Par Pharmaceutical Companies Inc. has begun marketing generic versions of the antihypertensive Lotrel and the antiarrhythmic drug Rythmol SR.


Par Pharmaceutical, Lotrel, Rythmol SR, generic versions, Amlodipine besylate, benazepril hydrochloride, antihypertensive, high blood pressure, propafenone SR, antiarrhythmic, irregular heart beat,




































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Par ships Lotrel, Rythmol SR generics

January 4th, 2011

WOODCLIFF LAKE, N.J. – Par Pharmaceutical Companies Inc. has begun marketing generic versions of the antihypertensive Lotrel and the antiarrhythmic drug Rythmol SR.

Par said Monday that it's shipping all strengths of amlodipine besylate and benazepril hydrochloride capsules, the generic version of Novartis' Lotrel medication for high blood pressure, and has been awarded 180 days of marketing exclusivity for the 5/320mg and 10/320mg strengths.

Amlodipine besylate and benazepril hydrochloride capsules are a combination tablet of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB), and benazepril, an angiotension converting enzyme (ACE) inhibitor. The combination tablets are indicated for the treatment of hypertension in patients not adequately controlled on monotherapy with either agent. According to IMS Health data, annual U.S. sales for these two Lotrel dosages are about $361 million, Par reported.

Meanwhile, Par said it's also rolling out 225-mg, 325-mg and 425-mg strengths of propafenone SR capsules, the generic version of GlaxoSmithKline's Rythmol SR medication for irregular heart beat, and has been granted 180 days of marketing exclusivity for the product.

Propafenone extended release capsules are indicated to prolong the time to recurrence of symptomatic atrial fibrillation in patients without structural heart disease. Citing IMS Health figures, Par said U.S. sales of Rythmol are approximately $121 million yearly.

Advertisement